|
3i plc 3i brings capital, knowledge and connections to the creation and development of businesses around the world. It invests in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on businesses with high growth potential and strong management. 3i invests in businesses across three continents through
local investment teams in Europe, Asia Pacific and the USA. To date,
3i has invested over £13.5 billion (including co-investment
funds). In the 12 months to 31st March 2001, an average of £7.8
million (including co-investment funds) was invested each working
day. 3i's current portfolio is valued at almost £6 billion. |
 |
|
Apax Partners Apax Partners is one of the world's leading private equity investment groups dedicated to high performance, entrepreneurial businesses. The group advises a number of Investment Pools with an accumulated total of EUR 12 billion and pursues a balanced equity portfolio strategy, investing in companies at all stages of development from start-up to buy-out. The group focuses primarily on six industry sectors: Telecommunications, Information Technologies, Media, Healthcare & Biotechnologies, Retail & Consumer Products, and Financial Services. Founded in 1972 in the United States and in Europe, Apax Partners currently has twelve offices worldwide. For further information on Apax Partners, visit www.apax.com. |
|
Atlas Venture Atlas Venture is the leading international, early-stage venture capital firm investing in communications, information technology and life sciences companies. With offices in Amsterdam, Boston, London, Menlo Park, Munich, Paris, and Seattle, Atlas Venture’s investments are split evenly between the United States and Europe. In 2000, our portfolio completed 14 IPOs and 11 acquisitions. Recent Atlas Venture portfolio company IPOs include Actelion (SWX: ATLN), deCODE genetics (Nasdaq: DCGN), Exelixis (Nasdaq: EXEL), Orchestream Ltd (LSE: OCH), SpeechWorks International (Nasdaq: SPWX) and Variagenics (Nasdaq: VGNX). Recent acquisitions of Atlas Venture portfolio companies include Cerulean Technology (Aether Systems), eGroups (Yahoo!), OnDisplay (Vignette), Trading Dynamics (Ariba), Omnia Communications (CIENA), RightPoint Software (E.piphany), Element 14 (Broadcom) and T.sqware (GlobeSpan). |
 |
|
BankInvest Bio Venture BankInvest was established as a mutual fund in 1969 by a number of local and regional banks, and today's owners represent a total balance of more than 35bn euros. With more than 30 years' experience as an asset management company and with more than 100,000 unit holders, institutional investors and corporations as clients, BankInvest is at present Denmark's third largest mutual fund manager and advisor. In June 2001, BankInvest's assets under management amounted to approximately 5bn euros, and these continue to grow extremely strongly. BankInvest manages portfolios of both bonds and equities. By using a selective investment strategy, BankInvest manages portfolios with focus on geographic areas as well as sector-specific portfolios. It is particularly within the fields of complex investments, e.g. biotechnology, information technology and emerging markets, that BankInvest distinguishes itself as an internationally leading asset management group. In the field of venture capital, BankInvest is also one of the leading venture capital providers in Denmark within the growth areas of biotechnology and information technology |
 |
|
Biotechnology Private Equity Advisors
|
|
Genzyme Corporation Genzyme Corporation is a publicly owned, fully integrated, diversified health care biotechnology company, committed to introducing innovative products and services for major, unmet medical needs, focused within three areas – specialty therapeutics, bio-surgery, and diagnostic products and genetic testing services. These are based upon the unique ability to integrate advanced technologies such as protein and cell therapy, gene therapy, small molecule drug discovery, polymer technology and biomaterials engineering. Genzyme operates through three divisions: Genzyme General (NASDAQ: GENZ) develops and markets therapeutic products and diagnostic products and services. It has five therapeutic products on the market and a strong pipeline of products in development focused on the treatment of genetic disorders and other chronic debilitating diseases with well-defined patient populations. Genzyme Biosurgery (NASDAQ GZBX) is a leader in the emerging market for biotechnology products used to improve or replace surgery. With products concentrated in orthopaedics and heart disease, it is developing a robust pipeline of biomaterials and biotherapeutics for these markets, as well as biomaterials with broader surgical applications. Genzyme Molecular Oncology (NASDAQ: GZMO) is positioned where the power and promise of genomics and biotechnology meet. It is utilizing its proprietary functional genomics and antigen discovery technology platforms to develop cancer vaccines and angiogenesis inhibitors. |
 |
|
Heidelberg Innovation IC Innovations (ICIL) is the wholly owned technology transfer company of Imperial College, London, employing 23 people. It is the largest technology transfer company in the UK and particularly differentiates itself by focusing on providing extensive “hands on” support to the process of spinning out new ventures. |
|
Imperial College Innovations IC Innovations (ICIL) is the wholly owned technology transfer company of Imperial College, London, employing 23 people. It is the largest technology transfer company in the UK and particularly differentiates itself by focusing on providing extensive “hands on” support to the process of spinning out new ventures. |
|
Isis Innovation Ltd Isis Innovation Ltd is the technology transfer company of the University of Oxford, commercialising the research generated by University researchers and owned by the University. Isis was established in 1988 and in 1997 started a major expansion phase; Isis is a wholly-owned subsidiary of the University of Oxford. The University assigns its intellectual property to Isis (where there are no pre-existing exploitation arrangements) and Isis then evaluates, protects, and markets the intellectual property. Isis provides researchers with commercial advice, funds patent applications and legal costs, and negotiates exploitation and spin-out company agreements. Isis works on projects from all areas of the University’s research activities: life science, physical science, humanities and business innovation ideas in a broader sense. |
|
MRC Technology Medical Research Council Technology (MRCT) acts as agent for the UK Medical Research Council in ‘technology transfer’. MRCT files and maintains a patent portfolio based on inventions in MRC Units around the country. MRCT uses a variety of commercial strategies to drive exploitation of the IP portfolio, including company formation and licensing. MRCT also has its own laboratories within which it executes commercial research programmes either industrially sponsored or funded as ‘own risk’. The tripartite mission of MRCT is to transfer MRC inventions into industry to help meet better health care, to help create jobs and wealth for the UK and to generate a flow of revenue back to the MRC. |
|
Nasdaq Europe Nasdaq’s European operation, Nasdaq Europe, a subsidiary of
The Nasdaq Stock Market, Inc has been created as a truly pan-European
exchange. Its unique structure and independence from any European
national market make it the perfect partner for innovative companies
and forward looking investors across Europe and beyond. The market
operates on a pan-European basis, with a unified structure including
a single Rule Book, a single membership, a dedicated trading platform,
and a seamless link to low cost, cross-border trading and settlement. Nasdaq has a global vision and with Nasdaq Europe that vision is now a step closer to becoming reality. |
 |
|
Novartis Venture Fund The Novartis Venture Fund expresses our conviction that economic growth and the creation of new jobs can be achieved in the long run only if new entrepreneurial initiatives develop and promising ideas become business reality. With a venture capital of 100 million Swiss francs, the Novartis Venture Fund supports new business projects that show exemplary entrepreneurial and innovative spirit in future-oriented areas, especially in the fields of Life Sciences and new technologies. |
|
Pharmacia Corporation Pharmacia Corporation is a first-tier global pharmaceutical company with an industry-leading growth rate, a robust product portfolio, a high-potential research & development pipeline, and a dynamic agricultural subsidiary in Monsanto Company. Pharmacia Corporation was created in April 2000 through the merger of Pharmacia & Upjohn with Monsanto Company and its G.D. Searle unit. Pharmacia employs 59,000 people worldwide and has research, manufacturing and administrative sales operations in more than 60 countries. At Pharmacia, we are meeting the needs of our key customers by harnessing cutting-edge science and technology, by attracting committed and motivated employees, by seeking to make partnering the hallmark of our external relationships, and by establishing ourselves as a good community citizen wherever we operate. In these and other ways, we continually enhance our future potential by increasing the long-term value of Pharmacia for our shareholders. To contact Pharmacia headquarters: |
|
Polaris Venture Partners With $2 billion under management, Polaris Venture Partners is a venture capital firm with investments across information and medical technology. Polaris takes an active lead role in its portfolio companies. The Polaris team is committed to helping entrepreneurs grow strong businesses by offering both operational and investment expertise. The firm currently supports more than 50 portfolio companies. Polaris-backed companies have included: Advanced Inhalation Research (AIR) (sold to Alkermes), Akamai Technologies, Inc. (NASDAQ: AKAM); Allaire Corporation; Aspect Medical Systems (NASDAQ: ASPM); Centra Software (NASDAQ:CTRA), deCODE Genetics (NASDAQ: DCGN); Paradigm Genetics (NASDAQ: PDGM), PowerSoft, and SolidWorks Corporation (sold to Dassault Systèmes). The company has offices in Boston and Seattle. More information about Polaris Venture Partners is available at www.polarisventures.com. |
|
Reabourne Technology Investment Management Ltd Reabourne Technology Investment Management Limited (“Reatech”) is a joint venture company owned by its senior executives and Close Brothers Group plc, a United Kingdom merchant banking group listed on the London Stock Exchange. Reatech has a multi-discipline team of portfolio managers with considerable experience in the technology and biotechnology sectors from a portfolio management perspective and practical experience in scientific research. Given the multi-discipline experience of the team and the international background of the members of Reatech, outperformance has come from a team approach to each portfolio. The disciplined investment process of Reatech has resulted in outperformance over a number of years. Reatech’s focus since inception and going forward is to provide the best in-depth analysis of technology companies on a global basis, with the objective of maximizing the total investment return for our partners over the medium to long-term. |
|
Schroder Ventures Life Sciences SVLS advises two private equity funds with total commitments of approximately $410m, focused on providing seed, start-up, early stage and expansion capital to life sciences companies in Europe, the US and Asia. In addition, SVLS advises the International Biotechnology Trust (IBT) plc, a publicly quoted investment trust listed on the London Stock Exchange (IBT.L), with a total net asset value of approximately £90m (as at 31 December 2001). The majority of IBT's investments are in quoted companies. For further information on SVLS, please visit www.svlifesciences.com. For further information on IBT, please visit www.internationalbiotrust.com Schroder Ventures Life Sciences in the UK is a trading name of Schroder Ventures Life Sciences Advisers (UK) Ltd, which is regulated by the FSA. |
|
Serono International. S.A.
|
|
SWX Swiss Exchange
The SWX Swiss Exchange is one of the world’s leading and most technologically advanced securities exchanges. In 1996, floor-based trading in Switzerland was supplanted by electronic trading. This fully automated trading, clearing and settlement system remains unique in the world. At the click of a mouse, an order is executed, cleared, paid for and confirmed. The SWX Swiss Exchange offers its customers first-rate securities exchange services and a broad range of investment products. The SWX
New Market provides innovative, international growth companies
– primarily from the life science, IT as well as the micro-
and nanotechnology industries – with access to the Swiss capital
market. A public offering in this segment affords issuing companies
a high degree of global visibility among investors, especially those
with a heightened interest in these sectors. An IPO in Switzerland
represents an attractive means of obtaining equity financing. |
 |